Learning Hub

The consortium of iProlepsis project for psoriatic arthritis consists of 15 partners from 9 countries. Discover more about project by visiting our website. About consortium partners iPROLEPSIS project coordinator Aristotle University of Thessaloniki Consortium consists of 15 partners from 9 countries. iPROLEPSIS consortium partners

Learn more about international events for psoriatic arthritis. Choose the event and book the date. Upcoming and past events iPROLEPSIS 7th Plenary meeting Dec 09, 2025, 9:00 AM – Dec 10, 2025, 4:00 PM Lisbon, Lisbon, Portugal More info LEARN MORE IEEE HealthCom 2025 Oct 21, 2025, 9:00 AM – 7:30 PM Abu Dhabi, United Arab Emirates More info Details HLTH Event 2025 Oct 19, 2025, 9:00 AM – Oct 22, 2025, 6:00 PM Las Vegas, Las Vegas, NV, USA More info Details GRAPPA Annual Meeting 2025 Jul 10, 2025, 11:00 AM – Jul 12, 2025, 8:00 PM Bogota, Colombia More info Details iPROLEPSIS 6th Plenary meeting May 13, 2025, 11:00 AM – May 14, 2025, 5:00 PM Oxford, UK More info Details 7th Polythematic Panhellenic Congress of Autoimmune Diseases, Rheumatology and Clinical Immunology Mar 28, 2025, 10:00 AM – Mar 30, 2025, 8:00 PM Portaria, Pelion More info Details Health Data Summit 2025 Mar 19, 2025, 9:00 AM – Mar 20, 2025, 7:00 PM The EGG, Brussels, Belgium More info Details iPROLEPSIS 5th Plenary Meeting Dec 02, 2024, 7:00 AM – Dec 03, 2024, 5:00 PM Athens, Greece More info Details DSAI 2024 Nov 13, 2024, 7:00 AM – Nov 15, 2024, 5:00 PM Khalifa University, Abu Dhabi, United Arab Emirates (UAE) More info Details PhD Open Days 2024 - 10th edition Nov 05, 2024, 7:00 PM – 11:00 PM Lisbon, Portugal More info Details How to communicate about and disseminate project results under Horizon Europe Cluster 1 ‘Health’ and Horizon 2020 Oct 24, 2024, 12:00 PM – 1:00 PM GMT+3 Webinar More info Details 16th Panhellenic EPEMY Conference Oct 05, 2024, 8:00 AM – Oct 06, 2024, 6:00 PM Ioannina, Greece More info DETAILS Psoriatic Arthritis Awareness Day Sep 28, 2024, 8:00 AM – 11:50 PM Virtual More info DETAILS European Researchers’ Night Sep 27, 2024, 8:00 AM – 7:40 PM Lisbon, Portugal More info DETAILS InnoHealth Forum 2024 Sep 20, 2024, 8:00 AM – Sep 21, 2024, 6:00 PM Larissa, Greece More info DETAILS IEEE EMBC 2024 Jul 15, 2024, 8:00 AM – Jul 19, 2024, 6:00 PM Orlando, Florida, USA More info DETAILS iPROLEPSIS 4th Plenary meeting Jul 01, 2024, 8:00 AM – Jul 02, 2024, 6:00 PM Munich, Germany More info DETAILS IFPA Conference 2024 Jun 27, 2024, 8:00 AM – Jun 29, 2024, 4:00 PM Stockholm, Sweden More info DETAILS Load More

Download iProlepsis project applications for psoriatic arthritis. Apps for download miPROLEPSIS app The miPROLEPSIS app facilitates the iPROLEPSIS-PDPID multicenter clinical study as a data collection tool that will enable the development of digital biomarkers for psoriatic arthritis symptoms and predictive models for inflammation exacerbation. More specifically, the app performs (i) passive data collection from the sensors of the smartwatch used in the study (i.e., Garmin Vivoactive 5), (ii) passive data collection from the accelerometer and gyroscope sensors of the smartphone, (iii) patient reported outcomes via questionnaires. Moreover, the app includes (i) a custom keyboard that captures the user’s typing dynamics and (ii) photo- and video-based activities for the collection of hand/feet photos and skeletal data related to joints flexibility, respectively. Note: The app can be used only by psoriatic arthritis patients that have enrolled to the PDPID study. This enrollment is available for patients in the UK, Netherlands, Portugal, and Greece. Information on how to enroll in the study and gain access to the miPROLEPSIS app will be provided soon. miPROLEPSIS app The miPROLEPSIS PDPID Study application functions as a data collection tool, utilized during the PDPID study, in order to produce datasets used for model generation and training. The app utilises both continuous and unobtrusive data collection (via bluetooth) from wearable devices, as well as user interactions (questionnaires, reporting etc). miPROLEPSIS Joint Landmarker app The miPROLEPSIS Joint Landmarker is an accompanying app of the miPROLEPSIS app that enables the video-based active tests feature. More specifically, a set of 6 hand and body movement exercises are presented and the user is asked to perform them in front of the smartphone camera. The app captures the videos and extracts skeletal data (coordinates of skeletal joints) locally. The skeletal data will be further analysed to develop digital biomarkers that assess the functionality and flexibility of joints. Note: The miPROLEPSIS Joint Landmarker app cannot be used without the miPROLEPSIS app. miPROLEPSIS Joint Landmarker app This app is a research app that accompanies the miPROLEPSIS app and aims to assess the physical functioning of people with Psoriatic Arthritis. More specifically, a set of 6 hand and body exercises are given and the user is asked to perform them in front of the smartphone camera. The app uses the collected videos to extract skeletal data (coordinates of skeletal joints), which are then sent to a cloud for further processing. Through the skeletal data processing, the aim is to identify whether a patient with Psoriatic Arthritis have difficulties in performing certain hand and body actions. The videos are immediately discarded and no personal information is retained, saved or transmitted.

iPROLEPSIS project will perform four different clinical studies in four different counties. Learn more about clinical studies by visiting iprolepsis.eu. About clinical studies iPROLEPSIS will perform four different clinical studies: 1. iPROLEPSIS-PDPID PsA digital phenotyping and inflammation drivers study. 2. iPROLEPSIS-MOJMI Mast cells and optoacoustics-enabled joint and microvascular imaging study. 3. iPROLEPSIS-IDBV Inflammation digital biomarkers validation study. 4. iPROLEPSIS-PPIDC Prevention of PsA inflammation through digital care: an intervention study. Clinical studies will be conducted in 5 countries: Netherlands UK Portugal Greece Germany Clinical studies PsA digital phenotyping and inflammation drivers study (iPROLEPSIS-PDPID) Development cohort of smartphone and smartwatch-based, AI-driven digital biomarkers for remote assessment and monitoring of people with psoriatic arthritis. Measure To develop novel smartphone- and smart device (belt, ring, camera) digital biomarkers for the assessment of inflammatory symptoms with special focus on the recognition of changes in movement patterns, pain, fatigue, morning stiffness in comparison to the gold standard – medical evaluation by clinical evaluation of the joints, tendons and skin. Predict To predict the change from uninflamed to inflamed using three triggers that may cause longstanding inflammation in psoriatic arthritis patients at risk for flare. Those three triggers are stress, mechanical stress and changes in the gut microbiome. OBJECTIVES Primary objectives to provide accurate, factual and clinically relevant records of the self-contained smartphone and smartwatch[1] based, AI-driven digital biomarker system in the detection of PsA specific inflammation; to predict accurate, factual and clinically relevant PsA specific inflammation. Secondary objectives to determine interperson reliability of the AI-driven digital biomarker system; to determine construct validity against clinical assessment of inflammation; to determine construct validity against patient assessment of inflammation; to determine clinically relevant changes in the AI-driven digital biomarker system; to determine minimal detectable difference in the AI-driven digital biomarker system; to assess the interperson variation of stress, mechanical stress and changes in gut microbiome on the occurrence of inflammation; to evaluate the compliance and satisfaction of the users with the smartphone and smartwatch-based, AI[1] driven digital monitoring system. The study is designed to develop a new way of measuring inflammation in patient with psoriatic arthritis. Definition of novel optoacoustic biomarkers of psoriasis and psoriatic arthritis (iPROLEPSIS-MOJMI) Mast cells and optoacoustics-enabled joint and microvascular imaging (iPROLEPSIS-MOJMI) study. The proposed multiscale (mesoscopic with RSOM and macroscopic with MSOT) approach aims at exploring and defining novel image-based biomarkers in order to describe the pathophysiological changes characterizing the disease and predict the transition from PsO to PsA. In other words, the unique multiscale nature of optoacoustics is expected to render skin microvasculature a window to later systemic (joint) effects of psoriasis and, thus, improve the prognosis in future patients with PsO. OBJECTIVES Primary objectives To define novel inflammatory mast cell, MSOT- and RSOM extracted biomarkers in patients with PsO/PsA. To quantify the changes of the novel inflammatory mast cell, MSOT- and RSOM-extracted biomarkers' with increasing disease severity. Secondary objectives To reveal correlations among the mast cells and the MSOT-and RSOM-extracted inflammatory biomarkers in patients with PsO/PsA. To define a novel index derived from mast cells, MSOT- and RSOM-based features to enable the early detection of PsA in patients with PsO or high risk for developing PsO. Inflammation digital biomarkers validation study (iPROLEPSIS-IDBV) Finding people that will convert from healthy to inflamed is a difficult task in Immune Mediated Inflammatory Disease (IMID). Initial symptoms look just like any other musculoskeletal disorder such as back pain, finger pain or achilles tendon problems. Over time symptoms can go either temporarily away, become chronic or become so severe that doctor care is needed. Early identification of people with IMID would greatly benefit their quality of live, keeps them at work and prevents high health care cost due to expensive medication. Digital biomarkers will give us for the first time the ability to study the conversion from musculoskeletal disorder to immune mediated inflammatory joint and tendon disease. The aim of this study to validate our digital biomarkers findings in PsA in psoriasis patients. OBJECTIVES Primary objectives to validate accurate, factual and clinically relevant records of the self-contained smartphone and smartwatch-based, AI-driven digital biomarker system in the detection of IMID specific joint or tendon inflammation. Secondary objectives to evaluate take up and acceptability of the digital biomarker in the wild; to evaluate the impact of missing data in detecting inflammation; to assess the number of false positives when data is captured in the wild; to assess the interperson variation of stress and mechanical stress. The aim is to identify inflammation with a software based medical device. This software will consist of an algorithm analysing data collected in the wild via smart devices: phone, watch, ring. Prevention of PsA inflammation through digital care: an intervention study (iPROLEPSIS-PPIDC) This study blends the findings of the newly developed digital biomarkers, the early findings of the triggers: stress, mechanical stress and changes in microbiome from PsA digital phenotyping and inflammation drivers study (iPROLEPSIS-PDPID), to provide a personalised approach to deal with the triggers with state-of-the-art interventions. OBJECTIVES Primary objectives In PsA patients with low disease activity a personalised intervention on food, physical activity and stress based on a personal profile of stress, mechanical stress and microbiome will be compared to usual care on inflammation development as detected by the newly developed digital biomarker system and clinical examination. Secondary objectives to evaluate take up and acceptability of the digital biomarker and intervention as part of normal medical treatment among patients, doctors and nurses; to assess compliance with the personalised intervention.

Download needed deliverables for iProlepsis project for psoriatic arthritis. Project deliverables D1.2 Data managmeent plan (initial version) WP1 - Management and coordination Read More D2.3 The iPROLEPSIS trustworthy AI framework WP2 - Knowledge mining, foundation and participatory design Read More D6.1 Project branding and communication channels WP6 - Dissemination, communication and exploitation Read More D2.1 Initial report on user research and co-creation process WP2 - Knowledge mining, foundation and participatory design Read More D4.2 The iPROLEPSIS patient and HCP apps (study version) WP4 - Development of the iPROLEPSIS digital health ecosystem for personalised preventive care Read More D6.2 Dissemination, exploitation and communication plan WP6 - Dissemination, communication and exploitation Read More D2.2 Initial report on the state-of-the-art and datasets WP2 - Knowledge mining, foundation and participatory design Read More D5.1 Study initiation package (iPROLEPSIS-PDPID study) WP5 - Clinical studies Read More D6.3 First report on project visibility and educational material WP6 - Dissemination, communication and exploitation Read More

Join iProlepsis project for the psoriatic arthritis community. Share your experience, expertise and observations, observations Community Information will be available soon.

iProlepsis project for psoriatic arthritis uses multi-source data analysis for guiding to a novel personalised digital care ecosystem and maximizes the impact. iPROLEPSIS project vision and impact maximisation Health-to-PsA transition through multi-source data analysis guiding to a novel personalised digital care ecosystem and impact maximisation through openness, visibility, networking and reuse of outcomes. Project vision Data analysis, iPROLEPSIS project goals, IoT technologies and mobile application. About Psoriatic Arthritis Psoriatic Arthritis (PsA) is a chronic, inflammatory disease, affecting the peripheral and axial skeleton, with a severe impact on patients’ quality-of-life. It is estimated that 1-2% of the general population has PsA, i.e., 5 to 10 million people in EU are affected . PsA is associated with psoriasis (PsO) and up to 30% of people living with PsO, i.e., at least 100 million people worldwide (WHO), are expected to develop PsA. The goal The goal of iPROLEPSIS is to propose a novel ecosystem that involves Real Worl Data (RWD) collection mechanisms and a powerful decision support system to provide new knowledge for the key actionable factors that affect the health-to-PsA transition, adopting a multiscale/ multifactorial approach, so, with the use of xAI-based models, to offer an efficient, effective, and clinically validated personalised digital care ecosystem for PsA patients. Technologies IoT sensing technologies and a mobile application will be at the heart of the RWD collection procedure, while retrospective and prospective multi-source data will be collected from the clinical partners’ databases, combined with open access ones. Through the analysis and visualisation of these data using AI predictive models and an intuitive visual analytics tool, respectively, the iPROLEPSIS will be able to propose personalized treatments (i.e., diet, physical activity, stress/fatigue/pain management), assisting doctors, caregivers, and hospitals towards the optimal management of PsA. Finally, through xAI techniques, iPROLEPSIS aims to facilitate hospitals and policy makers in gaining new insights towards better clinical practices, thus shaping future PsA treatment policies. Impact maximisation To ensure the successful implementation of the pathways towards impact in long-term, the project consortium aims at making iPROLEPSIS a reference for the fight against PsA by: 01 Creating an active iPROLEPSIS community of stakeholders. 02 Informing key stakeholders about results and their clinical innovation potential. 03 Making the outputs widely available for research and business purposes in the long term. 04 Increasing people with/at risk of PsA engagement for addressing their issues and concerns in order to increase their awareness and to build trust into new technology. 05 Reaching similar/relevant R&I projects for promoting networking and joint activities. 06 Establishing a forum/community for HCPs and authorities to develop new guidelines and standards. 07 Identifying exploitation mechanisms and activities, assessing the commercialization and applicability of the concepts and ideas. PROJECT OBJECTIVES

Download needed promo materials for iProlepsis project for psoriatic arthritis, such as posters, flyers, logos, and color palete. Promo materials to download 01 iPROLEPSIS Poster (A0) 02 iPROLEPSIS Flyer (A5) 03 iPROLEPSIS Roll-Up Poster Logo and color palette to download PNG, transparent background SVG, transparent background SVG, transparent background #212178 #B380FF #FFAACC #37C8AB #DEEBF7 PNG, white background WEBP, transparent background

Read publications about iProlepsis project for psoriatic arthritis. Discover insights and project progress. iPROLEPSIS project publications European advances in digital rheumatology: explainable insights and personalized digital health tools for psoriatic arthritis May 19, 2025 The shift from traditional to technology-based diagnosis and management of psoriatic arthritis (PsA) represents a significant evolution in patient care. Traditionally, PsA was diagnosed and managed through clinical evaluations, physical examinations, and basic imaging techniques. With the evolution of digital technologies, the PsA care is transforming, giving rise to the field of digital rheumatology. In this vein, Europe has invested in research initiatives, like iPROLEPSIS, that could accelerate this transformation and redefine PsA care within a digital world. In this Viewpoint we present the current clinical PsA landscape, highlight the PsA patients' interaction with the digital world, and showcase the novel iPROLEPSIS digital offerings. The latter scaffold digital rheumatology by identifying PsA key drivers. Moreover, they support personalized PsA risk prediction and improve early PsA detection. Furthermore, they enable precise PsA treatment strategies and digital therapeutics within a novel digital health ecosystem. Read More Developing Sensorimotor Art Games for Psoriatic Arthritis using Agile Storyboarding and Game Co-Design Processes June 28, 2024 Serious Games (SGs) have the potential to provide clinical care and enhance patients’ quality of life, while incorporating an element of entertainment. As part of the iPROLEPSIS Horizon Europe project, we introduce two Sensorimotor Art games designed as SGs to assist Psoriatic Arthritis (PsA) patients in managing their symptoms. Read More Can ChatGPT provide appropriate meal plans for NCD patients? May 30, 2024 Dietary habits significantly affect health conditions and are closely related to the onset and progression of non-communicable diseases (NCDs). Consequently, a well-balanced diet plays an important role in lessening the effects of various disorders, including NCDs. Read More Federated Learning Aggregation based on Weight Distribution Analysis October 3, 2023 Federated learning has recently been proposed as a solution to the problem of using private or sensitive data for training a central deep model, without exchanging the local data. Read More Hot topic debate: preventing psoriatic arthritis in patients with psoriasis November 11, 2024 Can effective treatment of psoriasis (PsO) prevent the development of psoriatic arthritis (PsA)? In a Hot Topic Debate at the 7th World Psoriasis & Psoriatic Arthritis Conference, Dr. Soriano and Dr. Ogdie, both experts in the field, presented contrasting views based on existing research and clinical studies.1 Dr. Soriano argued that biologic treatments for PsO may reduce PsA risk, citing several retrospective studies. On the other hand, Dr. Ogdie argued that current observational data are plagued by biases, making it difficult to conclude whether biologics play a protective role. The session outlined the complexity of this issue, with both speakers agreeing on the need for prospective randomised controlled trials, such as the ongoing PAMPA study, to provide definitive answers. Prof. Laura Coates added that identifying at-risk patients and intervening early to potentially prevent PsA may point to a strategic research approach to address these unanswered questions. Read More “The Kite” Breathing Serious Game: Agile Co-Design for Psoriatic Arthritis June 27, 2024 Serious Games (SGs) have been explored in healthcare for their potential as gamified means for disease assessment and/or intervention. Designing effective SGs requires attention to user requirements and iterative development. We introduce a SG design process for Psoriatic Arthritis (PsA) patients, aiming to enhance their quality of life. Read More AI nutrition recommendation using a deep generative model and ChatGPT May 31, 2024 In recent years, major advances in artificial intelligence (AI) have led to the development of powerful AI systems for use in the field of nutrition in order to enhance personalized dietary recommendations and improve overall health and well-being. Read More Digital biomarkers for psoriatic arthritis: a qualitative focus group study on patient-perceived opportunities and barriers October 30, 2024 The widespread adoption of wearables, for example, smartphones and smartwatches in the daily lives of the general population, allows passive monitoring of physiological and behavioural data in the real world. This qualitative study explores the perspective of psoriatic arthritis (PsA) patients towards these so-called digital biomarkers (dBMs). Read More ChatGPT in Nutrition: Trends Challenges and Future Directions June 26, 2024 A healthy and balanced diet is of paramount importance to the physical and psychological well-being of an individual, since unhealthy dietary choices have been linked with the occurrence of non-communicable diseases. Read More Developing Exergames for Psoriatic Arthritis using Agile Storyboarding and Game Design Processes June 26, 2024 Serious Games (SGs) offer significant potential in healthcare for disease assessment and intervention, enhancing patients’ quality of life. Exercise SGs, or Exergames, promote physical activity and mobility in a gamified environment, encouraging tailored exercises based on individual abilities and needs. Read More

iPROLEPSIS project newsletter Nov 6, 2025 Issue No. 10 iPROLEPSIS project newsletter No 10 Welcome! This is the 10th edition of the iPROLEPSIS newsletter, where we share the latest updates and progress from the project. READ THE NEWSLETTER Jul 1, 2025 Issue No. 9 iPROLEPSIS project newsletter No 9 Welcome! This is the 9th edition of the iPROLEPSIS newsletter, where we share the latest updates and progress from the project. READ THE NEWSLETTER Apr 28, 2025 Issue No. 8 iPROLEPSIS project newsletter No 8 Welcome! This is the 8th edition of the iPROLEPSIS newsletter, where we share the latest updates and progress from the project. READ THE NEWSLETTER Jan 28, 2025 Issue No. 7 iPROLEPSIS project newsletter No 7 Welcome! This is the 7th edition of the Newsletter series of the iPROLEPSIS project. In this issue, we highlight the insights on the future of digital biomarkers in rheumatology care, offer key information about PsA and practical advice to improve daily life, update about past events. READ THE NEWSLETTER Oct 9, 2024 Issue No. 6 iPROLEPSIS project newsletter No 6 Welcome! This is the 6th edition of the Newsletter series of the iPROLEPSIS project. In this issue, we highlight the release of the miPROLEPSIS and miPROLEPSIS Joint Landmarker apps, recent publications, reflections on Psoriatic Arthritis Awareness Day and Psoriasis Awareness Month, and key takeaways from recent events. READ THE NEWSLETTER Jul 9, 2024 Issue No. 5 iPROLEPSIS project newsletter No 5 Welcome! This is the 5th edition of the Newsletter series of the iPROLEPSIS project. In this newsletter issue, we delve into the updates and progress of the project activities, synergies and events. READ THE NEWSLETTER Mar 7, 2024 Issue No. 4 iPROLEPSIS project newsletter No 4 Welcome! This is the 4th edition of the Newsletter series of the iPROLEPSIS project. Let's explore the latest developments and advancements in our project activities, collaborations, and upcoming events. READ THE NEWSLETTER Nov 30, 2023 Issue No. 3 iPROLEPSIS project newsletter No 3 Welcome! This is the 3rd edition of the Newsletter series of the iPROLEPSIS project. In this newsletter issue, we delve into the updates and progress of the project activities, synergies and events. READ THE NEWSLETTER Sep 5, 2023 Issue No. 2 iPROLEPSIS project newsletter No 2 Welcome! This is the 2nd edition of the Newsletter series of the iPROLEPSIS project. In this newsletter issue, we delve into the transformative power of user research and co-creation in the healthcare innovation research process. READ THE NEWSLETTER Jul 3, 2023 Issue No. 1 iPROLEPSIS project newsletter No 1 Welcome! This is the 1st edition of the newsletter series of the iPROLEPSIS project! The 1st newsletter informs you about the iPROLEPSIS project, its vision, pillars and objectives, and the partners involved. READ THE NEWSLETTER